Ory et al.,13 dissecting the mechanism of ZOL resistance in osteosarcoma cells, indicated that prolonged treatment with ZOL increased the expression of FPPS, a critical enzyme in the mevalonate pathway that is inhibited by N-BPs, leading to a resistant phenotype. This evidence concerns the gene FDPS and osteosarcoma.